About US
Contact us
-
WuXi AppTec still sees sales growing and expansions rolling in 2024 despite concerns over US biosecurity billIn moments of great uncertainty, sometimes the best approach is to just press on. That seems to be the strategy being embraced at CDMO WuXi AppTec, whichissueda surprisingly upbeat 2024 forecast Mond2024/3/7
-
Takeda's Iclusig wins first-line FDA nod to treat rare Philadelphia chromosome-positive ALLTwelve years after Takeda'sIclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S. regulat2024/3/4
-
Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in ChinaThis year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian natio2024/3/4
-
IFF, after brief leadership stint under Merck's Frank Clyburn, pawns off pharma solutions business for $2.85BAfter a two-year stint under Merck & Co. veteran Frank Clyburn, New York’s International Flavors & Fragrances (IFF) is stripping away a major component of its healthcare persona. IFF—which da2024/3/1
-
Regeneron advances antitrust lawsuit against Novartis with appeals court's backingDid Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. The U.S. Court of App2024/3/1
-
GSK inks another Zantac settlement ahead of trial in CaliforniaAfter GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. Thursday, GSKsaidit has reach2024/2/2
-
Astellas inks deal to air Veozah ad in Super Bowl 2024 coverageAstellas is continuing its Veozah marketing blitz, signing up to air an ad for the drug just before kickoff in the upcoming Super Bowl to push the treatment of menopause-related vasomotor symptoms (V2024/2/2
-
Teva's refresh under new CEO Richard Francis moves into year 2 as Austedo, Ajovy and generics gain steamAfter charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the up and up, it’s all about maintaini2024/1/30
-
In continuing its transformation, Teva confirms plan to sell off API businessTeva’s transformation under new CEO Richard Francis is taking another turn. Wednesday, the companyconfirmedplans to sell its active pharmaceutical ingredients business as part of Francis’ “pivot to g2024/1/30
-
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begunBeaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arexvy2024/1/25